Telcon RF Pharmaceutical. Inc. (200230.KQ) Stock
Telcon RF Pharmaceutical. Inc.

Company profile
Telcon RF Pharmaceutical. reported revenue of 43.16 billion KRW for fiscal year 2025, up 14.0% from fiscal year 2024. Its largest business segment, Pharmaceutical/Bio Business Division, brought in 68% of segment revenue in fiscal year 2024; South Korea was the largest region with 84%. Our analysis of its filings shows revenue growing from 36.31 billion KRW in fiscal year 2023 to 43.16 billion KRW in fiscal year 2025, 9.0% a year on average.
What stands out
- It reported a net loss in each of its last 2 fiscal years, after a profit of 13.91 billion KRW in fiscal year 2023; the loss narrowed from 26.32 billion KRW in fiscal year 2024 to 11.46 billion KRW in fiscal year 2025.
- Revenue in fiscal year 2025 was the highest of the last 5 fiscal years.
Figures from company filings; latest fiscal year ended December 31, 2025.
About Telcon RF Pharmaceutical. Inc.
TELCON RF PHARMACEUTICAL. Inc. primarily engages in the development, production, and sale of RF coaxial connectors worldwide. It also provides coaxial couplers, distributors, and arresters, as well as cable assemblies; and pharmaceuticals. The company was formerly known as Telcon Co., Ltd. TELCON RF PHARMACEUTICAL. Inc. was founded in 1999 and is headquartered in Yongin-si, South Korea.
Largest shareholders
- Nuon Co., Ltd.14.49%
- L2l Holdings Co. Ltd.1.52%
- Joong-gil Kwon0.1055 %0.11%
Share of the company, as of September 25, 2026
Leadership
- Jin-Hun Lim — Chief Executive Officer and President
How much revenue does Telcon RF Pharmaceutical. make?
Telcon RF Pharmaceutical. reported 43.16 billion KRW in revenue for fiscal year 2025, up 14.0% from 37.87 billion KRW in fiscal year 2024.
What is Telcon RF Pharmaceutical.'s largest business segment?
Pharmaceutical/Bio Business Division, with 26.87 billion KRW or 68% of segment revenue in fiscal year 2024. Next: RF Business Division (32%).
Where does Telcon RF Pharmaceutical. make most of its revenue?
South Korea: 84% of revenue by region in fiscal year 2024, followed by North America (10%).
What companies are similar to Telcon RF Pharmaceutical.?
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Sanigen (188260.KQ), Aprogen Biologics Inc. (003060.KS), Seoul Pharma Co., Ltd (018680.KQ).
Has Telcon RF Pharmaceutical. made a profit in recent years?
Net income by fiscal year: FY2021, a loss of 23.10 billion KRW; FY2022, a loss of 42.08 billion KRW; FY2023, 13.91 billion KRW; FY2024, a loss of 26.32 billion KRW; FY2025, a loss of 11.46 billion KRW. It reported a net loss in 4 of these 5 years.
How has Telcon RF Pharmaceutical.'s revenue changed over the last 5 fiscal years?
Revenue by fiscal year: FY2021, 37.84 billion KRW; FY2022, 27.83 billion KRW; FY2023, 36.31 billion KRW; FY2024, 37.87 billion KRW; FY2025, 43.16 billion KRW.
Company Information
Contact & Links
Data as of .
How to cite: DataPorium, “Telcon RF Pharmaceutical. Inc. (200230.KQ)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/200230.KQ